Multiple sclerosis cost-effectiveness of therapy
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy |
|
Multiple sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Cost effectiveness
Given the morbidity and mortality associated with multiple sclerosis and the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.[1] Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar.[2] Controlling acute attack can reduce the economic burden of MS disease.
References
- ↑ Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (September 2009). "Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis". J Manag Care Pharm. 15 (7): 543–55. doi:10.18553/jmcp.2009.15.7.543. PMID 19739877.
- ↑ Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (October 1998). "A comprehensive assessment of the cost of multiple sclerosis in the United States". Mult. Scler. 4 (5): 419–25. doi:10.1177/135245859800400504. PMID 9839302.